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Chronic obstructive pulmonary disease (COPD) is characterized by both local
and systemic manifestations of inflammation. In particular, increased
numbers of neutrophils can be observed in the airway lumen and in the
blood of COPD patients. One early study on patients with COPD and chronic
bronchitis showed increasing levels of the neutrophil product myeloperox-
idase (MPO) during exacerbations, compared with control smokers who did
not suffer from COPD.1 In a more recent study on chronic smokers without
severe airway symptoms, we showed that the MPO concentrations in blood
increases during a six year-period.2 Thus, systemic neutrophil mobilization
may occur prior to the clinical manifestation of COPD.
Here, we determined whether MPO concentration in blood is altered during
exacerbations and/or during stable conditions in COPD patients with chronic
bronchitis (COPD-CB). We studied 60 well-defined COPD patients, 10
asymptomatic smokers and 10 healthy non-smokers. Blood samples were
harvested and analyzed for MPO every 15th week during 15 months and at ex-
acerbations. We also examined if the transcription of MPO is altered in blood
cells from COPD-CB patients.
The study shows that MPO protein and neutrophil concentrations but not MPO
mRNA increasedmarkedlyduringexacerbations inCOPD-CBpatients.Wedidnot
detect any correlation between mRNA and MPO protein during exacerbations.
Tentatively, our study indicates that there is increased release of MPO in
circulating or extravascular neutrophils during COPD exacerbations, and that
a post-transcriptional mechanism for MPO release is feasible.
Supported by the Swedish Heart-Lung Fund, the University of Gothenburg
and Karolinska Institute.
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Pulmonary hypertension (PH) is a serious complication to chronic obstructive
pulmonary disease (COPD). For early detection, we evaluated predictors of
mean pulmonary artery pressure (mPAP) and PH (mPAP25mmHg).
Altogether 97 COPD patients with mild to very severe airway obstruction
without left ventricle dysfunction were included. Pulmonary function tests,
right heart catheterizations and cardiopulmonary exercise tests (CPET) were
performed.
Multivariate analysis in a model including pulmonary function indices at rest,
adjusted for gender, age and height, showed that only PaO2 was a significant
predictor of mPAP (Regr. coeff. -2.35, 95% CI -3.02,-1.67, p<0.001). Indices
of airway obstruction and hyperinflation failed to predict mPAP. Logistic
regression analysis confirmed that only PaO2 was a significant predictor of
PH (p<0.001). ROC curve analyses with optimal cut-off values for PaO2 at
rest and at peak exercise were applied to test their diagnostic accuracy
for PH. For PaO2 at rest, area under the curve (AUC) was 0.78 (95% CI
0.67, 0.87) and cut-off value  9.5 kPa. For PaO2 at peak exercise, AUC
was 0.81 (95% CI 0.70, 0.93) and cut-off value  8.5 kPa. By combining
PaO2 at rest and peak exercise, pulmonary hypertension was possible to pre-
dict with a detection rate of 76% and a false-positive rate of 10%. When vari-
ables from CPET were included in multiple regression analyses, mPAP was
predicted by oxygen uptake, ventilation and PaO2 at peak exercise (p<0.05).
Conclusion: PaO2 at rest and PaO2 at peak exercise are important to eval-
uate when assessing the presence of PH in COPD.
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Fibrotic events participate in pathogenesis of chronic obstructive pulmonary
disease (COPD) (1). Our aim was to study the expression of alpha-smooth
muscle actin (a-SMA), tenascin-C and EDA-fibronectin in emphysema and
COPD.
Lung tissue specimens from central bronchi and peripheral lung tissue were
analyzed by immunohistochemistry. Number of a-SMA (as a marker of
myofibroblast), tenascin-C and EDA-fibronectin positive areas in alveolar
walls, bronchioles and bronchi were counted in the patients with normal
Abstracts S5lung, COPD and emphysema. Immunohistochemical findings were correlated
with the clinical data.
Damaged alveolar walls formed distal alveolar distensions, which contained
a-SMA positive cells as well as occasionally tenascin-C and EDA-fibronectin.
a-SMA-positive cells located in bronchi as foci of variable sizes. Tenascin-C
expression in bronchi was analyzed as previously showing positivity a) in
basal cells and basement membrane (BM), b) in basal cells plus BM plus
stroma underneath BM, and c) in abovementioned areas plus widely in the
stroma (2). Most of the bronchioles revealed positive cells for a-SMA, while
the expression for tenascin-C and EDA-fibronectin was mainly negative. The
number of a-SMA positive distal alveolar distensions was higher in non-
smokers and normal lung than in smokers and COPD. The number of a-SMA
positive foci in bronchi associated with obstruction.
We concluded that a-SMA-positive distensions in alveolar walls might be
involved in regenerative process of alveoli in normal and diseased lung.
Moreover, foci of a-SMA positive cells in bronchial walls together with the
excess of tenascin-C seemed to reflect remodelling process of large airways
in COPD.
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During wound healing processes fibroblasts accounts for wound closure by
adopting a contractile phenotype and produce extracellular matrix (ECM)
molecules. During normal wound healing the process is terminated when the
wound has healed and the initial trigger disappears. However when the
trigger persists, as is the case in COPD with the repeated exposure of
cigarette smoke, the wound healing process becomes pathological and the
fibroblast phenotype is likely to be altered. Our aim was to investigate the
repair capability, defined as ECM production and contractility, in centrally
(bronchial) and distally (alveolar) derived fibroblasts from severe COPD
patients and control subjects.
The repair functions were different in centrally and distally derived
fibroblasts from COPD patients compared to the corresponding cells from
control subjects. Distally derived fibroblasts from COPD patients were more
contractile and this was dependent on increased ROCK1 activity. In addition,
these cells had enhanced production of the proteoglycan versican. Versican
have been suggested to interfere with de novo synthesis of elastin and may
thus be important in formation of emphysema. Centrally derived fibroblasts
from COPD patients had a lower basal production of the basement mem-
brane-stabilizing proteoglycan perlecan which may indicate alterations of
the bronchial basement membrane in COPD. To summarize, our results sug-
gest that fibroblasts from COPD patients have altered repair functions.
Importantly, there was a difference in function between bronchial and alve-
olar fibroblasts which may reflect the different pathological processes in
these sites.
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Background: MFAP4 is a glycoprotein, co-localized with elastin and microfi-
brils in elastic fibres (Schlosser, Thomsen et al. (2006)). MFAP4 knock-out
mice develop mild emphysema (not yet published data). We hypothesized
that circulating MFAP4 reflects elastin degradation and can be used as a
marker of emphysema severity.
Methods: Plasma levels of MFAP4 (pMFAP4) were determined by Alphalisa
assay in 76 Danish COPD patients from the multicentre ECLIPSE study,
(Vestbo, Anderson et al. 2008) 50 smokers and 54 non-smokers. Controls
were healthy blooddonors. Associations between ln-transformed pMFAP4
levels and clinical outcomes were assessed by Pearson product moment cor-
relation test and multiple regression analysis. Age, gender, packyears and
carbonmonnoxide (as a indicator of current smoking) were included as
covariates.
Results: Levels of lnMFAP4 were significantly lower in smokers (mean:364ng/
mL) than in non-smokers (471 ng/mL) and COPD patients (457 ng/mL).
LnMFAP4 associated significantly with MMRC (Modified Medical Research
Council score) in COPD patients (b: 0.09 p<0.05). There was a tendency of
association between the composite BODE index (BMI, Obstruction index, Dys-
pnea score and Exercise capacity), it was borderline significant when adjust-
ing for covariates (b:0.03 p:0.07). LnpMFAP4 did not associate significantly
with FEV1 (b:-0.002 pZ0.24) or obstruction index (b:-0.004 pZ0.13).
Conclusion: MFAP4 plasma levels are supressed by smoking, and are associ-
ated to dyspnea in COPD patients.
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Smoking is the most important environmental risk factor for the develop-
ment of COPD. Computer tomography (CT) imaging provides means of
quantifying pulmonary structure and function. We hypothesized that the
inflammation in smokers may be mirrored by an altered attenuation on high
resolution CT (HRCT).
Forty smokers with normal lung function (20 men, 20 women, age mean 54;
range 45-65; 3512 pack years, 40 healthy neversmokers, age 57 (45-65) and 40
patientswithCOPD,GOLD stage I-II, age 59 (45-65) (3811 pack year, 31 current
smokers and 9 exsmokers) underwent inspiratory HRCT scans . Values between
-750 and -900 HUwere considered as high attenuation areas and the percentage
of the lung volumewith this attenuation range was calculated. Bronchoalveolar
lavage, BAL, was performed according to a standardized protocol. Cell
concentration and differential cell counts in BAL fluid were recorded.
The percentage of lung area with high attenuation was increased in smokers
(44%  5.7; mean SD) compared to neversmokers (38%  5.6) and COPD
exsmokers (33%  4.5) (p<0.001 and p<0.05 respectively) indicating denser
lungs in smokers. COPD current smokers (41%  5.0) did not differ from that
of smokers with normal lung function. A significant positive correlation
(p<0.001) between cell concentration in BAL and HRCT areas with high
density was found in current smokers. There was no significant correlation
between cell concentrations in BAL and HRCT density in neversmokers and
COPD exsmokers. Female neversmokers had denser lungs than males (40% 
1.3 vs 36% 1.3, pZ0.03). This was also the case for smokers with normal
lung function (females 46%  1.3 vs males 42% +1.2; p<0.04).
The increased density in smokers compared to nonsmokers may mirror an
inflammatory response induced by cigarette smoke and is correlated to
current smoking status rather than smoking history. This hypothesis is
strengthened by a positive correlation between lung attenuation and cell
concentration in the lower respiratory tract. A gender difference was found
suggesting a more intense inflammation in female smokers than in males.
